Karyopharm Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $154.68M.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $5.79M.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $0.00.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $29.29M, a 195.81% increase year-over-year.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for fiscal 2022 was $189.76M, a 1816.20% increase from fiscal 2021.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for fiscal 2021 was $9.90M, a 93.88% decline from fiscal 2020.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for fiscal 2020 was $161.78M, a 250.23% increase from fiscal 2019.
- Karyopharm Therapeutics Inc. stock issued during period, value, new issues for fiscal 2019 was $46.19M, a 68.30% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $154.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $189.76M 10-K · filed 2025-02-19 |
| 2022-09-30 | $5.79M 10-Q · filed 2023-11-02 | $35.08M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $29.29M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $29.29M 10-Q · filed 2023-05-04 | $29.29M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $9.90M 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $9.88M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.88M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $9.90M 10-Q · filed 2022-05-05 | $9.88M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $161.78M 10-K · filed 2023-02-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $193.43M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $207.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $161.80M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $31.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $46.19M 10-K · filed 2022-03-01 |
| 2019-09-30 | $14.56M 10-Q · filed 2020-11-02 | |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $145.71M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | |
| 2018-06-30 | $145.72M 10-Q · filed 2019-08-07 | |
| 2017-12-31 | $74.89M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $50.57M 10-K · filed 2017-03-16 | |
| 2015-12-31 | $90.83M 10-K · filed 2018-03-15 | |
| 2014-12-31 | $112.84M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $113.16M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |